Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Analyst Coverage

Analyst Coverage

The following analysts currently issue reports on Shield Therapeutics:

Company Analyst
Liberum Graham Doyle
Peel Hunt Amy Walker
Edison Dr Susie Jana
Hardman & Co Dr Dorothea Hill
Capital Network Emma Ulker
finnCap Mark Brewer

All of finnCap, Edison, Hardman & Co and Capital Network’s research on their corporate clients are free to view via the following links:

finnCap – There is a simple registration process for all non-institutional users and their corporate research is readily available:

finnCap

Hardman & Co

Capital Network/ Proactive Investors

Any opinions estimates or forecasts regarding the Company’s performance made by such analysts are theirs alone and do not represent opinions, forecasts or predictions of the Company or its Management. You should, therefore, not place undue reliance on the content of any such analyst report or statement.

Any reports issued may have become out of date following publication and should be read accordingly.

18 Mar 2020

AEGIS-2 update

Shield Therapeutics

Shield Therapeutics (STX) has announced a technical update to findings from the AEGIS-H2H post-marketing study, which evaluated Feraccru/Accrufer vers...

Read more
27 Jan 2020

2019 a landmark year

Shield Therapeutics

Today’s 2019 business and trading update highlights a landmark year for Shield Therapeutics. Feraccru/Accrufer (oral ferric maltol) is making in...

Read more
13 Jan 2020

Feraccru out-licensed in China

Shield Therapeutics

Shield Therapeutics has kick-started 2020 by securing an out-licensing deal in China for its primary asset, Feraccru/Accrufer. The exclusive deal with...

Read more
08 Aug 2019

The land of opportunity awaits Accrufer

Shield Therapeutics

Shield Therapeutics’ interim results highlight a momentous year to date, with the FDA approval of primary asset Feraccru/Accrufer, for the treat...

Read more
26 Jul 2019

FDA approval attained, sales execution now key

Shield Therapeutics

Shield Therapeutics’ primary asset, Feraccru, has been approved by the FDA for the treatment of iron deficiency in patients with any underlying ...

Read more
09 Jul 2019

Bitesize briefing - Shield Therapeutics

Bitesize briefing - Shield Therapeutics

Shield Therapeutics is a UK-based, speciality pharmaceut...

Read more
09 Jul 2019

Executive interview

Shield Therapeutics

Shield Therapeutics is a UK-based, speciality pharmaceutical company with a primary focus on commercialising its drug Feraccru, which is approved in E...

Read more
03 Apr 2019

Next step US Feraccru approval

Shield Therapeutics

Shield Therapeutics reported FY18 results in line with our expectations. Total revenue of £11.9m included the £11.0m upfront payment from ...

Read more
25 Mar 2019

Executive interview - Shield Therapeutics

Executive interview - Shield Therapeutics

Shield Therapeutics is a commercial-stage speciality pharmaceutical company based in the United Kingdom that listed on AIM in 2016. Its primary focus ...

Read more
04 Mar 2019

Feraccru performs again in a Phase III study

Shield Therapeutics

Shield Therapeutics has announced positive top-line data from a Phase IIIb study (AEGIS-H2H) for Feraccru, a CHMP-approved oral formulation of iron po...

Read more
19 Feb 2019

Fortified for growth

Shield Therapeutics

Shield Therapeutics is focused on the development and commercialisation of Feraccru, a CHMP-approved oral formulation of iron positioned for the treat...

Read more